Related Experiment Video
Updated: Jun 9, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Emerging drugs in endometrial cancers
Ozden Altundag1, Polat Dursun, Ali Ayhan
1Baskent University School of Medicine, Department of Medical Oncology, Ankara, Turkey.
Expert Opinion on Emerging Drugs
|September 11, 2010
Summary
Endometrial cancer treatment is evolving, with surgery for cure and chemotherapy for advanced disease. Novel targeted therapies show promise for improving outcomes in endometrial adenocarcinomas.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Translational Cancer Research
Background:
- Endometrial cancer is the most common gynecologic malignancy.
- Current treatment strategies for endometrial cancer are undergoing rapid evolution.
Purpose of the Study:
- To review current and future medical treatment options for endometrial cancer.
- To provide an overview of established and emerging therapies.
Main Methods:
- Review of current literature on endometrial cancer treatment.
- Discussion of cytotoxic chemotherapy, hormonal therapy, and targeted therapies.
- Analysis of treatment efficacy and toxicity.
Main Results:
- Surgery is the cornerstone of curative therapy.
- Cytotoxic chemotherapy, particularly combination regimens, is standard for advanced disease.
- Hormonal therapy and emerging targeted agents (mTOR inhibitors, antiangiogenic agents) offer new avenues.
Conclusions:
- Ongoing clinical trials aim to integrate novel agents into treatment algorithms.
- The goal is to improve outcomes for patients with endometrial adenocarcinomas.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...